Onxeo announces the evolution and reinforcement of its Board of Directors // DANISH TRANSLATION: Onxeo udvider og styrker bestyrelsen

NB! FOR DANISH TRANSLATION, SCROLL DOWN.

  • Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors as Board Observers
  • Joseph Zakrzewski elected as Onxeo Chairman

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced that Prof. Jean-Pierre Kinet, M.D., of Harvard Medical School, and Jean-Pierre Bizzari, M.D., world-renowned experts in oncology with over 20 years of pharma and biotech experience in the United States, have been appointed Observers to the Board of Directors, effective immediately. Their appointments as full board members will be submitted to the shareholders during the next annual shareholders meeting.

Dr. Bizzari has dedicated his professional life to clinical development, especially in oncology, and has brought to the market several leading cancer drugs – including ABRAXANE® (nab-paclitaxel), ELOXATIN® (oxaliplatin), and TAXOTERE® (docetaxel). During his most recent experience as Executive Vice-President of Clinical Oncology Development at Celgene, Dr. Bizzari developed hematology and solid tumors therapeutics, including an HDAC inhibitor.

Dr. Kinet will bring to Onxeo his research expertise in immunology and oncology acquired through various positions in academia, including his current position as Professor of Pathology at Harvard Medical School (Boston – USA).  Both will provide Onxeo with access to a very valuable network of academic, biotech, and pharma leaders in the United States and in Europe and will further enhance the current high level of expertise of the company’s Board of Directors.

In addition, Mr. Joseph Zakrzewski has been elected Chairman of Onxeo’s Board of Directors, as announced in October 2015. He is replacing Patrick Langlois, who has resigned. Mr. Zakrzewski has more than 25 years of experience in the global healthcare industry with a strong focus in the United States.

Joseph Zakrzewski commented: “We are proud to welcome Drs. Kinet and Bizzari to our team. Their appointments will bring additional knowledge and expertise of both research and clinical development in Oncology to the Board and Onxeo’s teams, as we are leading our key compounds towards advanced clinical development and expanding our research programs with preclinical experimentations. Their experience and intimate knowledge of the academic and biotech fields and network worldwide will be key strengths in growing the company through a strong and powerful pipeline. The appointments of these two renowned and respected members of the biopharma industry will strengthen our position as a leader in orphan oncology research and development. I also would like to thank former Chairman Patrick Langlois for his commitment to Onxeo’s development through its focus on high potential orphan oncology products. Under his leadership, the company underwent significant transformation, paving the way for it to become a key player in the orphan oncology space. I am excited to join a company with such a robust ambition as Onxeo.

Jean-Pierre Bizzari, M.D., added: “Joining Onxeo’s Board of Directors is a real opportunity to contribute to the development of breakthrough treatments in orphan oncology. I am excited to offer my knowledge and experience in the clinical development of anticancer agents to Onxeo’s promising pipeline.”

Prof. Jean-Pierre Kinet, M.D., stated: “With its two lead products under development and an ambitious preclinical program, Onxeo can make a significant contribution to R&D in the orphan oncology field. I am looking forward to contributing to the reinforcement of Onxeo’s position in this field.”

Biographies:

JEAN-PIERRE BIZZARI, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active board member in various biotech companies, such as Transgene in France, Halozyme Therapeutics and Celator Pharmaceuticals in the US. He has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses.

Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene.

Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.

Prof. JEAN-PIERRE KINET, M.D., is one of the most prominent immunology experts worldwide, most famous for discovering some of the genes and proteins constituting the immunoglobulin E receptor. These scientific breakthroughs contributed to the introduction of new diagnostic tools and therapies for diseases related to immune system dysregulation. He also is the co-founder and founder of two biotech companies (AB Science and Astarix), and is a board member of several other biotech companies in Europe.

He is Professor of Pathology at Harvard Medical School (Boston – USA). He is also a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA.  Jean-Pierre Kinet is a member of the Scientific Advisory Board of UCB Pharma and Managing Partner of iXLife Capital. Jean-Pierre Kinet received his medical degree from the University of Liege (Belgium), and was trained in internal medicine at the Liège University hospital. He has written over 200 publications and holds 10 American and global patents. In 1997, he received the NIH “Inventor Award” and in 2004 the prestigious “NIH Merit Award”. He was decorated in 2000 as a Knight of the National Order of Merit of the French Republic.

JOSEPH ZAKRZEWSKI has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Insulet Corporation, and Onxeo.  Mr. Zakrzewski also serves on the board of a number of privately held companies, is advisor to a number of entities, and is involved in a number of philanthropic activities.  He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 through 2013 successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, the world’s largest healthcare-dedicated investment firm in 2010 and 2011. Prior to this, he was Chairman, President and Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 through 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 through 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including R&D, business development, supply chain and manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance, and business development focused on Lilly’s biotechnology and protein business. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a worldwide basis. A US citizen, Mr. Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Download PDF

//

DANISH TRANSLATION:

  • Dr. Jean-Pierre Kinet fra Harvard Medical School og Dr. Jean-Pierre Bizzari, begge internationalt anerkendte kræfteksperter, indtræder i Onxeos bestyrelse som observatører
  • Joseph Zakrzewski er udnævnt til ny bestyrelsesformand for Onxeo

Paris (Frankrig), København (Danmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt selskab med speciale i udvikling af lægemidler til behandling af sjældne kræftsygdomme, har i dag meddelt, at Jean-Pierre Kinet, M.D., fra Harvard Medical School og Jean-Pierre Bizzari, M.D. – begge internationalt anerkendte kræfteksperter med mere end 20 års erfaring fra den amerikanske lægemiddel- og biotekindustri – indtræder i bestyrelsen som observatører med virkning fra i dag. Der vil på næste generalforsamling blive stillet forslag om at udpege begge til fuldgyldige bestyrelsesmedlemmer.

Dr. Bizzari har viet sit arbejdsliv til klinisk udvikling, specielt på kræftområdet, og har ført flere førende kræftbehandlingsmidler på markedet, herunder ABRAXANE® (nab-paclitaxel), ELOXATIN® (oxaliplatin) og TAXOTERE® (docetaxel). Han har senest fungeret som Executive Vice President for Clinical Oncology Development hos Celgene, hvor han udviklede behandlinger mod blodkræftsygdomme og solide tumorer, herunder en HDAC-hæmmer.

Dr. Kinet kommer med omfattende forskningserfaring inden for immunologi og onkologi, som han har opnået i forbindelse med forskellige poster inden for den akademiske verden, herunder sin nuværende stilling som professor i patologi på Harvard Medical School i Boston, USA. De har begge to adgang til et yderst værdifuldt netværk af ledere fra den akademiske verden og fra biotek- og medicinalbranchen i USA og Europa, og de vil yderligere højne den allerede store ekspertise i Onxeos bestyrelse.

Samtidig er Joseph Zakrzewski som offentliggjort i oktober 2015 udnævnt til formand for Onxeos bestyrelse. Han erstatter Patrick Langlois, som er trådt ud af bestyrelsen. Joseph Zakrzewski har mere end 25 års erfaring fra den internationale lægemiddelindustri med hovedvægten på USA.

Joseph Zakrzewski udtaler: “Vi er stolte af at kunne byde velkommen til Dr. Kinet og Dr. Bizzari. Begge vil supplere bestyrelsen og Onxeos stab af medarbejdere med yderligere viden og ekspertise inden for forskning og klinisk udvikling på kræftområdet på et tidspunkt, hvor vores førende stoffer er på vej ind i den sene udviklingsfase, og hvor vi udvider vores forskningsprogrammer med prækliniske forsøg. Begge vil med deres erfaring og store indsigt i de akademiske og bioteknologiske områder samt deres verdensomspændende netværk bidrage til at videreudvikle selskabet via en stærk og bred pipeline. Med udnævnelsen af disse to anerkendte og respekterede medlemmer af den biofarmaceutiske industri styrker vi vores position som en førende aktør inden for forskning og udvikling af lægemidler til behandling af sjældne kræftsygdomme. Jeg vil samtidig gerne takke vores afgående formand, Patrick Langlois, for hans store engagement i Onxeos udvikling via selskabets fokus på attraktive produkter inden for behandling af sjældne kræftsygdomme. Under hans lederskab har selskabet gennemgået en markant udvikling, som har gjort, at vi i dag er førende inden for lægemidler til behandling af sjældne kræftsygdomme. Jeg er glad for at blive en del af en virksomhed med så stærke ambitioner”.

Jean-Pierre Bizzari, M.D., tilføjer: “Som medlem af Onxeos bestyrelse får man en enestående mulighed for at bidrage til udviklingen af banebrydende lægemidler til behandling af sjældne kræftsygdomme. Jeg er glad for at kunne dele min viden og erfaring og dermed bidrage til den kliniske udvikling af kræftbehandlingsmidler til Onxeos lovende pipeline”.

Professor Jean-Pierre Kinet, M.D., udtaler: “Med to hovedprodukter under udvikling og et ambitiøst præklinisk program kan Onxeo bidrage betragteligt til forskningen og udviklingen af lægemidler til behandling af sjældne kræftsygdomme. Jeg glæder mig til at bidrage til at styrke Onxeos position på dette område”.

Biografi:

JEAN-PIERRE BIZZARI, M.D., var fra 2008 til 2015 Executive Vice President og Group Head for Clinical Oncology Development (USA, Europa og Asien/Japan) hos Celgene. Han har bidraget til den kliniske udvikling af flere kræftbehandlingsmidler, herunder Taxotere®, Eloxatin®, Abraxane® og Irinotecan® (CPT-11). Som internationalt anerkendt kræftekspert er han medlem af French National Cancer Institutes (INCa) Scientific Advisory Board og af European Organisation of Research and Treatment of Cancer (EORTC) samt formand for the New Drug Advisory Committee. Jean-Pierre Bizzari er samtidig aktivt bestyrelsesmedlem i en række biotekselskaber, herunder Transgene i Frankrig samt Halozyme Therapeutics og Celator Pharmaceuticals i USA. Han har publiceret mere end 70 artikler i anerkendte tidsskrifter og præsenteret mere end 160 abstracts i forbindelse med videnskabelige kongresser.

Bizzari indledte sin karriere i lægemiddelindustrien i 1983, da han blev Head of Oncology ved Institut de Recherches Internationales SERVIER (Frankrig). I 1993 blev han Vice President of Clinical Oncology hos Rhône-Poulenc Rorer, først med base i Paris og sidenhen, fra 1997, i Collegeville i Pennsylvania, USA. Fra 2002 til 2008 var han Vice President of Clinical Oncology Development hos Sanofi-Aventis i Malvern, Pennsylvania, før han kom til Celgene.

Jean-Pierre Bizzari er uddannet læge med speciale i onkologi fra universitetet i Nice (Frankrig) og har arbejdet på Pitié-Salpêtrière-hospitalet i Paris samt Ontario Cancer Institute og Montreal Mac Gill Cancer Center i Canada.

Professor JEAN-PIERRE KINET, M.D., er en af verdens førende eksperter i immunologi og er mest kendt for at have opdaget nogle af de gener og proteiner, der udgør immunglobulin E-receptoren. Disse videnskabelige gennembrud har bidraget til indførelsen af nye diagnostiske værktøjer og behandlinger af sygdomme relateret til forstyrrelser i immunforsvaret. Han er desuden medstifter og stifter af to biotekselskaber (AB Science og Astarix) og er bestyrelsesmedlem i en række andre biotekselskaber i Europa.

Han er professor i patologi på Harvard Medical School i Boston, USA. Han sidder desuden i en række ekspertudvalg i National Institutes of Health (NIH) i USA og er medlem af det medicinske udvalg i American Asthma Foundation i USA. Jean-Pierre Kinet er medlem af UCB Pharmas Scientific Advisory Board og Managing Partner i iXLife Capital. Jean-Pierre Kinet fik sin lægefaglige uddannelse på University of Liege (Belgien) og sin praktiske uddannelse i intern medicin på Liège University Hospital. Han har skrevet over 200 publikationer og er indehaver af ti amerikanske og globale patenter. I 1997 modtog han NIH’s “Inventor Award” og i 2004 den prestigefyldte pris “NIH Merit Award”. Han blev i 2000 slået til ridder af den franske “Ordre National du Mérite”.

JOSEPH ZAKRZEWSKI har mere end 25 års erfaring fra biotek- og lægemiddelindustrien. Ud over i Onxeo er han bestyrelsesmedlem i de børsnoterede virksomheder Acceleron Pharmaceuticals, Amarin Pharmaceuticals og Insulet Corporation. Han sidder også i bestyrelsen for en række private selskaber, er rådgiver for adskillige virksomheder og er involveret i en række filantropiske projekter. Fra 2010 til 2013 var han bestyrelsesformand og CEO for Amarin Pharmaceuticals, et børsnoteret selskab med fokus på udvikling og kommercialisering af hjerte-kar-medicin baseret på Omega 3-fedtsyrer, hvor han var med til at udvikle og lancere Vascepa®. I perioden 2010-2011 var han venturepartner i Orbimed, verdens største investeringsselskab med fokus på sundhedsindustrien. Før dette var han fra 2007 til 2010 bestyrelsesformand og CEO for Xcellerex, et privatejet selskab med fokus på kommercialisering af en egenudviklet næstegenerations-teknologi til fremstilling af biologiske lægemidler og vacciner. Xcellerex er siden blevet solgt til GE Healthcare. Fra 2005 til 2007 var Joseph Zakrzewski Chief Operating Officer hos Reliant Pharmaceuticals, som fremstiller lægemidler til behandling af hjerte-kar-sygdomme, hvor han havde ansvaret for lægemiddelaktiviteterne, herunder forskning og udvikling, forretningsudvikling, supply chain og produktion, kvalitet, IT og compliance. Reliant Pharmaceuticals blev solgt til GlaxoSmithKline i 2007. Fra 1988 til 2004 beklædte Joseph Zakrzewski en række ledende stillinger i Eli Lilly & Company inden for bl.a. forskning og udvikling, produktion, økonomi og forretningsudviking med fokus på den bioteknologiske og proteinbaserede forretning. Han sluttede sin karriere hos Eli Lilly som Vice President for Corporate Business Development, hvor han havde det globale ansvar for al forretningsudvikling. Joseph Zakrzewski er amerikansk statsborger og har en bachelorgrad i Chemical Engineering (1986), en masters-grad i Biochemical Engineering fra Drexel University (1988) samt en MBA i finansiering fra Indiana University (1992).

Download PDF